A Proof of Concept (POC) Study, Phase II, Open Label, Randomized, Standard Care - Controlled, Single Center Study Evaluating the Safety and Efficacy of Human, Alpha-1 Antitrypsin (AAT) [GLASSIA®] Treatment in First Lung Transplantation

Trial Profile

A Proof of Concept (POC) Study, Phase II, Open Label, Randomized, Standard Care - Controlled, Single Center Study Evaluating the Safety and Efficacy of Human, Alpha-1 Antitrypsin (AAT) [GLASSIA®] Treatment in First Lung Transplantation

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Alpha 1-antitrypsin (Primary)
  • Indications Lung transplant rejection
  • Focus Adverse reactions; Proof of concept
  • Sponsors Kamada
  • Most Recent Events

    • 01 Aug 2017 According to a Kamada media release, the company expected to have an interim analysis from this study in second half of 2017.
    • 01 Aug 2017 Status changed from recruiting to active, no longer recruiting, according to a Kamada media release.
    • 06 Apr 2016 Status changed from not yet recruiting to recruiting, according to a Kamada Ltd. media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top